Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VO659 long-term safety extension in Huntington's disease and spinocerebellar ataxia types 1 and 3
NL-OMON61777Phase 2Not yet recruiting
- Sponsor
- Vico Therapeutics
- Start
- Nov 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of VO659 in Huntington disease (HD), spinocerebellar ataxia type 1 (SCA1) and machado-joseph disease (MJD) (3 cohorts), sponsored by Vico Therapeutics. Primary endpoints: Treatment-emergent safety events, Clinical safety assessments and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
VO659
03
Conditions
Huntington disease (HD)spinocerebellar ataxia type 1 (SCA1)machado-joseph disease (MJD)
Beyond the preview
Go deeper on NL-OMON61777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61777.